Miranda Cesare, Garlatti Elena, Da Porto Andrea, Rinaldo Elena, Grazioli Silvia, Zanette Giorgio, Tonizzo Maurizio
Clinic of Endocrinology and Metabolism Diseases, Pordenone Hospital, Pordenone, Italy.
Internal Medicine, Santa Maria degli Angeli Hospital, Pordenone, Italy.
Arch Med Sci Atheroscler Dis. 2023 Feb 23;8:e1-e10. doi: 10.5114/amsad/160950. eCollection 2023.
The coronavirus disease 2019 (COVID-19) pandemic has revolutionized the priorities of the medical society worldwide. Although most patients infected with SARS-CoV-2 exhibit respiratory symptoms, other organs may also be involved, including the liver, often resulting in liver injury. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its prevalence is expected to increase together with the epidemics of type 2 diabetes and obesity. Data about liver injury during COVID-19 are numerous, while overviews of this infection in patients with NAFLD, both in terms of respiratory and liver, are emerging. In this review, we summarise the current research focusing on COVID-19 in NAFLD patients and discuss the association between liver injury in COVID-19 subjects and non-alcoholic fatty liver disease.
2019年冠状病毒病（COVID-19）大流行彻底改变了全球医学界的优先事项。尽管大多数感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的患者表现出呼吸道症状，但其他器官也可能受累，包括肝脏，常导致肝损伤。非酒精性脂肪性肝病（NAFLD）是世界上最常见的慢性肝病，预计其患病率将随着2型糖尿病和肥胖症的流行而增加。关于COVID-19期间肝损伤的数据众多，而针对NAFLD患者在呼吸道和肝脏方面的这种感染的综述也不断涌现。在本综述中，我们总结了当前针对NAFLD患者中COVID-19的研究，并讨论了COVID-19患者肝损伤与非酒精性脂肪性肝病之间的关联。
